Status:
COMPLETED
D-serine Monotherapy for Schizophrenia
Lead Sponsor:
Herzog Hospital
Collaborating Sponsors:
Israel Science Foundation
Conditions:
Schizophrenia
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
A first generation of clinical studies, performed during the last decade, demonstrates that adjuvant treatment with compounds that enhance NMDAR-mediated neurotransmission due to their agonistic activ...
Eligibility Criteria
Inclusion
- Age 18-70;
- Diagnosis of schizophrenia/schizoaffective disorder according to DSM-IV criteria.
- Stable dose antipsychotic treatment for at least 4 weeks;
- Treatment refractoriness according to Kane et al.(1988) criteria.
Exclusion
- Meeting criteria for other DSM-IV Axis I diagnoses ;
- Substance abuse or alcoholism during entire lifetime;
- Are judged clinically to be at suicidal or homicidal risk;
- Female patients who are pregnant or lactating; female patients who are not pregnant or lactating, if sexually active, must be using medically accepted means of contraception;
- Patients with known intolerance to OLA treatment or who have failed an adequate trial of OLA (at least 6 weeks) at high doses (20 mg/day or higher);
- Patients treated with depot antipsychotics or ECT within the eight weeks prior to study entry.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00816894
Start Date
January 1 2009
End Date
February 1 2013
Last Update
December 10 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ezrath Nashim - Herzog Memorial Hospital
Jerusalem, Israel, 91035